State of Wyoming Takes Position in BioMarin Pharmaceutical Inc. $BMRN

State of Wyoming acquired a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 9,980 shares of the biotechnology company’s stock, valued at approximately $571,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BMRN. GSA Capital Partners LLP bought a new stake in shares of BioMarin Pharmaceutical in the 2nd quarter worth about $944,000. Summit Global Investments bought a new position in BioMarin Pharmaceutical during the 2nd quarter valued at about $1,869,000. Handelsbanken Fonder AB boosted its position in BioMarin Pharmaceutical by 7.2% in the second quarter. Handelsbanken Fonder AB now owns 62,700 shares of the biotechnology company’s stock valued at $3,588,000 after buying an additional 4,200 shares in the last quarter. Everhart Financial Group Inc. boosted its position in BioMarin Pharmaceutical by 34.2% in the second quarter. Everhart Financial Group Inc. now owns 6,995 shares of the biotechnology company’s stock valued at $400,000 after buying an additional 1,784 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in BioMarin Pharmaceutical by 43.5% during the second quarter. GAMMA Investing LLC now owns 2,422 shares of the biotechnology company’s stock worth $139,000 after buying an additional 734 shares during the last quarter. 98.71% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently issued reports on BMRN shares. Sanford C. Bernstein cut their target price on shares of BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating for the company in a research note on Tuesday, May 5th. Oppenheimer increased their price target on BioMarin Pharmaceutical from $95.00 to $97.00 and gave the stock an “outperform” rating in a research report on Friday, August 7th. Weiss Ratings cut BioMarin Pharmaceutical from a “hold (c-)” rating to a “sell (d)” rating in a report on Tuesday, August 11th. Morgan Stanley lifted their price objective on BioMarin Pharmaceutical from $119.00 to $124.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Finally, Canaccord Genuity Group boosted their price objective on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, BioMarin Pharmaceutical has an average rating of “Moderate Buy” and a consensus price target of $88.00.

BioMarin Pharmaceutical Stock Performance

BMRN opened at $67.36 on Monday. BioMarin Pharmaceutical Inc. has a 1-year low of $49.26 and a 1-year high of $70.98. The stock has a market capitalization of $13.04 billion, a PE ratio of 182.05, a PEG ratio of 0.47 and a beta of 0.24. The company has a current ratio of 2.39, a quick ratio of 1.32 and a debt-to-equity ratio of 0.56. The firm has a 50-day moving average price of $59.56 and a two-hundred day moving average price of $57.51.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating the consensus estimate of $0.95 by $0.25. The business had revenue of $989.71 million for the quarter, compared to analysts’ expectations of $932.03 million. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. BioMarin Pharmaceutical’s revenue was up 20.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.44 earnings per share. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. As a group, equities analysts anticipate that BioMarin Pharmaceutical Inc. will post 4.22 earnings per share for the current fiscal year.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.